
|Articles|May 20, 2020
ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
Innovations in glaucoma poised for breakthrough in 2026 (and what might hold them back)
3
FDA approvals in 2025: What changed and why it matters for ophthalmologists
4
PRIMAvera study: Central vision improvement with subretinal implant
5












































